spot_img

about fansalaran

FanSalaran is a comprehensive media platform dedicated to reporting and clarifying the significant achievements of pharmaceutical companies. In collaboration with passionate and motivated young journalists, this website consistently strives to showcase the country's successes in order to inspire and encourage the hardworking individuals of this land.

dorost

UAE activates new mechanism to strengthen drug supply security

The mechanism seeks to address monopolistic dynamics that can limit market access, constrain pricing flexibility and increase vulnerability to...

Oman’s Health Ministry budget nears RO1 bln; over 20 new projects planned

MOH says over 20 new health projects planned, including new facilities and hospital expansions. Oman’s Ministry of Health (MOH) is...

Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs

Danish drugmaker Novo Nordisk has partnered with U.S.-based Vivtex Corp in a deal worth up to $2.1 billion to...

K-beauty ranks No. 1 in Japan’s imported cosmetics market for 4 consecutive years

K-beauty claimed the top spot in Japan’s imported cosmetics market again in 2025, marking its fourth consecutive year at...

KFSH Successfully Implements Advanced Technology to Treat Prostate Cancer

King Faisal Specialist Hospital and Research Centre (KFSH) in Riyadh has successfully introduced a pioneering high-intensity focused ultrasound (HIFU)...

GSK to buy 35Pharma for $950 million in CEO Miel’s second major deal

GSK has agreed to pay $950 million in cash for Canadian biotech 35Pharma, it said on Wednesday, marking the...
spot_imgspot_img

AstraZeneca boosts CEO Soriot’s pay to about $24 million for 2025

AstraZeneca Chief Executive Pascal Soriot’s 2025 pay rose 6.4% to 17.7 million pounds ($23.87 million) boosted by higher annual...

Novo Nordisk, United Biotechnology obesity drug trial shows 19.7% weight loss

Novo Nordisk said on Tuesday its ‌triple agonist UBT251 of ‌the receptors for GLP-1, GIP and glucagon, jointly developed...

Barclays slashes sales forecasts for Novo’s CagriSema by more than 80%

Barclays analysts on Tuesday slashed their peak sales forecasts for Novo Nordisk's next-generation obesity drug CagriSema to just $2...

AbbVie launches new podcast focused on accelerating drug development

With an eye—and ear—toward spreading the perseverance and optimism ingrained in the field of science, AbbVie has launched a...

Frontier Biotechnologies strikes up to $1 billion deal with GSK

Frontier Biotechnologies said on Tuesday it has struck a deal with GSK GSK, granting the British drugmaker worldwide rights...

Researchers create ‘personalized’ artificial skin to study atopic dermatitis itch

A Korean research team has successfully developed a “next-generation 3D artificial skin model” that replicates the unique lesion environment...